Top

A Case Series: Activity of Pembro-Lenvatinib in dMMR EC Who Have Not Responded to Pembro-Mono

Panelists discuss how the pembrolizumab-lenvatinib combination offers promising efficacy as a second-line therapy for patients with mismatch repair deficiency (dMMR) endometrial cancer (EC) who did not respond to pembrolizumab monotherapy, with an emphasis on biomarker-driven treatment decisions, managing toxicity, and the need for further studies to refine patient selection and treatment strategies.

Summary for Physicians: Interpretation of Findings From Key Studies and Case Reports in Advanced EC Dr Birrer to Dr Naumann: Activity of Pembrolizumab and Lenvatinib in dMMR EC Patients Who Did Not Respond to Pembrolizumab Monotherapy: A Case Series (P. Rose et al., Gynecol Oncol Rep, 2023) Summary: Dr Naumann interprets the findings of P.

Rose et al. (2023) , emphasizing that the pembrolizumab-lenvatinib combination shows promising efficacy for patients with dMMR EC who did not respond to pembrolizumab monotherapy . The combination may overcome resistance and provide a beneficial second-line treatment option for these patients.

He also underscores the importance of biomarker-driven treatment and the need for close monitoring for adverse events associated with this combination. Finally, he highlights the need for further studies to refine this approach and better understand how to optimize patient selection and treatment regimens..